These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36758444)

  • 1. Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.
    Badura-Stronka M; Kuszel Ł; Wencel-Warot A; Cudnoch K; Wołyńska K; Rutkowska K; Steinborn B; Płoski R
    Epilepsy Res; 2023 Feb; 190():107101. PubMed ID: 36758444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
    Dibbens LM; Hodgson BL; Helbig KL; Oliver KL; Mulley JC; Berkovic SF; Scheffer IE
    Epilepsy Res; 2012 Sep; 101(3):277-9. PubMed ID: 22551666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A
    Calame DG; Herman I; Riviello JJ
    Epilepsy Behav Rep; 2021; 15():100425. PubMed ID: 33554103
    [No Abstract]   [Full Text] [Related]  

  • 8. Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.
    Douaud M; Feve K; Pituello F; Gourichon D; Boitard S; Leguern E; Coquerelle G; Vieaud A; Batini C; Naquet R; Vignal A; Tixier-Boichard M; Pitel F
    PLoS One; 2011; 6(10):e26932. PubMed ID: 22046416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
    Ohno Y; Tokudome K
    CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.
    Menten-Dedoyart C; Serrano Navacerrada ME; Bartholome O; Sánchez Gil J; Neirinckx V; Wislet S; Becker G; Plenevaux A; Van den Ackerveken P; Rogister B
    PLoS One; 2016; 11(11):e0166525. PubMed ID: 27861538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
    Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
    Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking.
    Harper CB; Small C; Davenport EC; Low DW; Smillie KJ; Martínez-Mármol R; Meunier FA; Cousin MA
    J Neurosci; 2020 Jun; 40(23):4586-4595. PubMed ID: 32341095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
    CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
    Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M
    Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
    Tokudome K; Shimizu S; Serikawa T; Ohno Y
    Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
    de Groot M; Aronica E; Heimans JJ; Reijneveld JC
    Neurology; 2011 Aug; 77(6):532-9. PubMed ID: 21795655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.